As CEA has been a long sought-after vaccine target in multiple cancer types, our findings are important, as they, for the first time, demonstrate the feasibility of anti-tumor responses in CEA-expressing tumors using AAV, a vector not associated with any pathology and that possesses minimal risk for insertional mutations, overcoming obstacles that have been viewed as major safety concerns with other viral vectors. This evidence concerns the gene CEACAM5 and neoplasm.